Boston Trust Walden Corp Has $44.71 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Boston Trust Walden Corp boosted its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 134,575 shares of the company’s stock after buying an additional 4,920 shares during the period. Boston Trust Walden Corp owned approximately 0.43% of Medpace worth $44,710,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of MEDP. R Squared Ltd bought a new position in shares of Medpace during the 4th quarter worth approximately $30,000. Stone House Investment Management LLC bought a new position in shares of Medpace in the third quarter worth $33,000. Ashton Thomas Securities LLC purchased a new position in Medpace during the third quarter valued at approximately $37,000. Capital Performance Advisors LLP purchased a new position in Medpace during the third quarter worth about $46,000. Finally, True Wealth Design LLC increased its holdings in shares of Medpace by 16,800.0% in the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after buying an additional 168 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MEDP. Redburn Atlantic initiated coverage on Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 target price for the company. TD Cowen cut their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Truist Financial reduced their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. William Blair reiterated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $381.44.

Medpace Trading Down 1.7 %

NASDAQ MEDP opened at $343.38 on Tuesday. Medpace Holdings, Inc. has a 12 month low of $291.15 and a 12 month high of $459.77. The stock’s fifty day moving average price is $342.50 and its 200-day moving average price is $351.36. The stock has a market cap of $10.67 billion, a P/E ratio of 30.07, a P/E/G ratio of 1.79 and a beta of 1.36.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.